Tumorad
Spago’s CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”
2024 has marked a defining chapter for Spago Nanomedical, solidifying its position in radionuclide therapy. By focusing its energy...
Spago Nanomedical’s SAB on Tumorad’s potential
Recently, Spago Nanomedical announced that the company has...
Spago Nanomedicals CDO om studieansökan
Spago Nanomedical lämnade nyligen in ansökan om att...
Tumorad clinical start around the corner for Spago Nanomedical
Encouraged by positive preclinical data with Tumorad, Spago...
Spago Nanomedical redovisar avancemang
ACS Omega
Spago Nanomedical publicerar positiva prekliniska data
Prekliniska data med Spago Nanomedicals radionuklidkoncept Tumorad har...
Spago Nanomedical startar fas IIa-studie i endometrios
Lundabaserade Spago Nanomedical meddelade nyligen att bolaget fått...
Spago Nanomedical i hett område
Radionuklidterapier mot cancer är ett hett område som...
Spago Nanomedical om höstens nyhetsflöde
Under andra kvartalet genomförde Lundabolaget Spago Nanomedical en...
Spago Nanomedical går mot klinik med Tumorad
Strax innan halvårsskiftet meddelade Lundabaserade Spago Nanomedical att...
Spago Nanomedical tar kliv med kapitalinjektion
Lundabolaget Spago Nanomedical tar in kapital via en...
Spago Nanomedical mot klinik med tydlig plan
First North-listade Spago Nanomedicals vd Mats Hansen berättade...
